Chalazion is a round, slowly emerging, localized swelling, in the form of a cyst located on the lower or upper eyelid. (Chalazion is the Greek word for "hailstone" which represents the size of the lump that makes up the cyst.) The usually painless, grainy (granulomatous) mass is due to inflammation, obstruction, and retained secretions of one of the glands that lubricates the edge of the eyelids. These glands secrete sebum, an oily, protective fluid. If one or more of the ducts that drain these glands is blocked, the sebum accumulates under the skin to form a cyst.
In rare cases, if the cyst is large, blurred vision may result due to pressure on the cornea, the front, clear portion of the eye through which light passes. In some affected individuals, chalazia may disappear spontaneously. However, in other cases, treatment may be required. Individuals with chronic inflammation of the eyelids (blepharitis) may be prone to recurrences.
Chalazion is a chronic inflammation of the meibomian gland, a gland of the eyelids that secretes an oily, protective fluid. It is characterized by an irritation and swelling of the eyelid. There may be a small, round, moveable swelling of the meibomian gland. The inflammation is usually painless unless it enlarges and causes an inflammation of the eyelids’ membrane (conjunctiva). Chalazion tends to occur more often on he upper eyelid than on the lower eyelid.
The exact cause of chalazion is not known. It is thought to be caused by a blockage of the duct of the oil-producing meibomian gland. When oil cannot flow through the duct, it accumulates, resulting in a lump on the eyelid. Unlike styes, which form on the edge of the eyelids, chalazia are not the result of bacterial infection.
Chalazia will often subside after a few months. The application of hot compresses, and topical antibiotic ointments such as bacitracin and erythromycin, may be effective. If necessary, surgical removal can be done under local anesthesia, usually in an ophthalmologist's office. The healing process may require wearing an eye patch for about a day.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:710.
Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:1295.
Dhaliwal U, Arora VK, Singh N, et al. Cytopathology of chalazia. Diagn Cytopathol. 2004;31.
D’hermies F, Fayet B, Meyer A. [Chalazion mimicking an eyelid tumor.] J Fr Ophthalmol. 2004;27:202-05. French.
Ozdal PC, Cordere F, Callejo S, et al. Accuracy of the clinical diagnosis of chalazion. Eye. 2004;18:135-38.
Shiramizu KM, Kreiger AE, McCannel CA. Severe visual loss caused by ocular perforation during chalazion removal. Am J Ophthalmol. 2004;137:204-05.
Ho SY, Lai JS. Subcutaneous steroid injection as treatment for chalazion: prospective case series. Hong Kong Med J. 2002;8:18-20.
Mustafa TA, Oriafage IH. Three methods of treatment of chalazia in children. Saudi Med J. 2001;22:968-72.
Jackson TL, Beun L. A prospective study of cost, patient satisfaction, and outcome of treatment of chalazion by medical and nursing staff. Br J Ophthalmol. 2000;84:782-85.
FROM THE INTERNET
Douglas RS. Medical Encyclopedia: Chalazion. MedlinePlus. Update Date: 12/22/2002. 2pp.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100